Cardiac tissues containing semiconductor nanomaterials and methods of preparing and using the same

Patent metadata

Field	Value
Publication number	US-10988735-B2
Application number	US-201615543701-A
Country	US
Kind code	B2
Filing date	Jan 15, 2016
Priority date	Jan 16, 2015
Publication date	Apr 27, 2021
Grant date	Apr 27, 2021

Abstract

Described herein are tissues containing semiconductor nanomaterials. In some embodiments, the tissues include vascular cells, cardiomyocytes, and/or cardiac fibroblasts. The tissue may be scaffold-free. In some embodiments, the tissue includes an electrically conductive network. The tissue may exhibit synchronized electrical signal propagation within the tissue. In some embodiments, the tissue exhibits increased functional assembly of cardiac cells and/or increased cardiac specific functions compared to a cardiac tissue prepared using a conventional tissue culture method. Methods of preparing and using such tissues are also described herein.

First claim

That which is claimed is:

1. A tissue comprising cardiac cells, a semiconductor nanomaterial, and an electrically conductive microenvironment,
wherein the electrically conductive microenvironment consists of an electrically conductive network within the tissue, wherein the electrically conductive network comprises the cardiac cells and the semiconductor nanomaterial;
wherein the semiconductor nanomaterial is incorporated within the tissue and the semiconductor nanomaterial is present in the tissue in an amount of about 0.00001% to about 1% by weight of the semiconductor nanomaterial per volume of the tissue;
wherein the tissue is scaffold-free and is a three-dimensional tissue; and
wherein the tissue is a spheroid or an aggregate.

2. The tissue of claim 1 , wherein the cardiac cells comprise cardiomyocytes and/or cardiac fibroblasts.

3. The tissue of claim 1 , wherein the semiconductor nanomaterial is an n-type or p-type semiconductor nanomaterial.

4. The tissue of claim 1 , wherein the semiconductor nanomaterial is biocompatible and/or biodegradable.

5. The tissue of claim 1 , wherein the semiconductor nanomaterial has a diameter in a range of about 10 nm to about 200 nm.

6. The tissue of claim 1 , wherein the semiconductor nanomaterial has a length of about 1 μm to about 20 μm.

7. The tissue of claim 1 , wherein the semiconductor nanomaterial comprises a silicon nanomaterial.

8. The tissue of claim 7 , wherein the silicon nanomaterial is a silicon nanowire and/or nanotube.

9. The tissue of claim 7 , wherein the silicon nanomaterial has a silicon:phosphorous ratio in a range of about 10:1 to about 10000:1 and/or a silicon:borane ratio in a range of about 10:1 to about 10000:1.

10. The tissue of claim 1 , wherein the semiconductor nanomaterial has a conductivity in a range of about 0.001 μS/μm to about 2000 μS/μm.

11. The tissue of claim 1 , further comprising vascular cells.

12. The tissue of claim 1 , wherein the semiconductor nanomaterial is present in the tissue in an amount of about 0.00001% to about 0.01% by weight of the semiconductor nanomaterial per volume of the tissue, and
wherein the semiconductor nanomaterial has a diameter of about 10 nm to about 200 nm and a length of about 1 μm to about 20 μm.

13. The tissue of claim 1 , wherein the tissue is prepared from a cell culture having a ratio of cardiac cells to semiconductor nanomaterial in a range of about 0.5:1 to about 100:1 (number of cells:number of semiconductor nanomaterials).

14. The tissue of claim 1 , wherein the electrically conductive network provides synchronized electrical signal propagation within the tissue.

15. The tissue of claim 1 , wherein the tissue is a functional cardiac microtissue.

16. The tissue of claim 1 , wherein the tissue is in the form of a spheroid.

17. A method of screening a compound or composition, the method comprising:
introducing and/or contacting the compound or composition to a tissue of claim 1 .

18. The method of claim 17 , further comprising detecting a response to the compound or composition.

19. A method of repairing cardiac tissue in a subject, the method comprising implanting a tissue of claim 1 into the cardiac tissue of the subject.

Assignees

• Univ Clemson Res Foundation
• Musc Found For Res Dev
• Univ Chicago

Inventors

• Mei Ying
• Yu Tan
• Richards Dylan
• Menick Donald R
• Tian Bozhi

Classifications

• A61L27/3886

  comprising two or more cell types · CPC title

• C12N2533/10

  Mineral substrates · CPC title

• C12N2506/45

  from artificially induced pluripotent stem cells · CPC title

• C12N2503/02

  Drug screening · CPC title

• A61L27/3804

  characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells · CPC title